Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Phase 2 Active not recruiting 7 enrolled Neurocrine Biosciences

NaSingle-groupOpen-labelTreatment

Summary

The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).

Timeline

Start: 2025-09-30
Primary completion: 2029-09-06
Completion: 2029-10-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Crinecerfont	Small molecule	—	Oral

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

Summary

Timeline

Drugs

Indications